Ace investor Vijay Kedia chooses a stake in this Microcap Pharma share

December 30, 2025

Adapting to the investment principles of investment gurus starts with tailoring them to personal risk tolerance, time horizon and goals such as long-term growth. This customization avoids blind copying and uses proven strategies for private investors.

One esteemed investor whose every investment attracts attention is Vijay Kedia.

Who is Vijay Kedia?

Vijay Kedia is a fixture in the world of Indian stock markets. Widely regarded as a market maestro, his reputation for selecting successful mid-cap stocks has made his portfolio a guiding light for retail investors.

Kedia started his journey into the stock market at the age of 19 and comes from his roots in a family of stockbrokers. At the age of 33, he founded Kedia Securities, cementing his place in the investment world.

In this editorial we discuss a stock in which he recently acquired a stake.

Which shares did Vijay Kedia buy and why?

Vijay Kedia-backed Kedia Securities has bought microcap shares of Mangalam Drugs and Organics.

The top investor acquired 137,794 shares in the company in a bulk deal worth Rs 3.32 million. At the time of writing, the stock has reached the top of the circuit filter on December 30, 2025.

While the reasons for his choice remain unclear, here is something that may explain the decision.

#1 Improve performance

Despite still incurring losses, Mangalam Drugs and Organics showed better performance in the quarter ended September 2025. The company, which had reported a loss of Rs 137.28 million in the June 2025 quarter, has significantly reduced this to Rs 72.46 million in the September 2025 quarter.

This performance boost may have led to Vijay Kedia-backed Kedia Securities buying shares in the company.

#2 Repeat the export order

Mangalam Drugs and Organics has received a significant repeat export order for an anti-malarial API from one of its renowned international customers. The total value of the order is approximately Rs 150 million. This order will likely account for a significant portion of revenue in the coming quarters.

What now?

In late 2024, the company announced the expansion of its anti-malarial API portfolio with the introduction of Pyronaridine. This move, which includes prequalification by WHO and collaboration with the Bill and Melinda Gates Foundation, could potentially be a growth driver in the future.

Mangalam Drugs and Organics has taken several steps to improve net profit margins for the coming financial years.

The company is also taking steps to gradually diversify its product range. Sales of anti-inflammatory and blood pressure lowering products have shown positive trends, contributing to a more diversified revenue stream.

Moreover, according to management, Sulfadoxine has huge potential for the company and has shown commercial viability this year.

Mangalam Drugs and Organics has been successful in reducing the raw material cost of Sulfadoxine per unit. This product is expected to increase sales and net profit in the coming years. There are plans to increase its production capacity.

How Have Mangalam Medicines & Organics Stocks Performed?

In the last five days, shares of Mangalam Drugs and Organics have risen from Rs 24.05 to Rs 26.28. Over the past month, the stock price is up about 2%. Over the past year, shares have lost 77%.

The stock touched its high of Rs 129.9 on January 10, 2025 and its 52-week low of Rs 22.7 on December 29, 2025.

About Mangalam medicines and organic substances

Mangalam Drugs & Organics produces active pharmaceutical ingredients and intermediates.

It has a multi-product manufacturing facility at two locations and its own research and development laboratory recognized by the Department of Scientific & Industrial Research, Delhi Government of India (DSIR). Over the past five decades, Mangalam Drugs has built a reputation as a single stop destination for first-line anti-malarial APIs. The company also has a diversified product range with business synergies and economies of scale.

To know what is moving the Indian stock markets today, check out the latest stock market updates here.

Investors should evaluate the company’s fundamentals, corporate governance and stock valuations as key factors when conducting due diligence before making investment decisions.

Disclaimer: This article is for informational purposes only. It is not a stock recommendation and should not be treated as such. Read more about our referral services here…